Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51143
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12791]
Metadata
Show full item record
REIMAGINING LEPROSY ELIMINATION WITH AI ANALYSIS OF A COMBINATION OF SKIN LESION IMAGES WITH DEMOGRAPHIC AND CLINICAL DATA
Inteligência artificial
AI
Diagnóstico baseado em imagem
Dermatologia
Lesões de pele
Al4lepra
Artificial intelligence
AI
Image-based diagnosis
Dermatology
Skin lesions
Al4leprosy
Author
Barbieri, Raquel Rodrigues
Yixi, Xu
Setian, Lucy
Santos, Paulo Thiago de Souza
Trivedi, Anusua
Cristofono, Jim
Bhering, Ricardo
White, Kevin
Sales, Anna Maria
Miller, Geralyn
Nery, José Augusto da Costa
Sharman, Michael
Bumann, Richard
Shun, Zhang
Goldust, Mohamad
Sarno, Euzenir Nunes
Mirza, Fareed
Cavaliero, Arielle
Timmer, Sander
Bonfiglioli, Elena
Smith, Cairns
Scollard, David
Navarini, Alexander A.
Aerts, Ann
Lavista Ferres, Juan
Moraes, Milton Ozório
Yixi, Xu
Setian, Lucy
Santos, Paulo Thiago de Souza
Trivedi, Anusua
Cristofono, Jim
Bhering, Ricardo
White, Kevin
Sales, Anna Maria
Miller, Geralyn
Nery, José Augusto da Costa
Sharman, Michael
Bumann, Richard
Shun, Zhang
Goldust, Mohamad
Sarno, Euzenir Nunes
Mirza, Fareed
Cavaliero, Arielle
Timmer, Sander
Bonfiglioli, Elena
Smith, Cairns
Scollard, David
Navarini, Alexander A.
Aerts, Ann
Lavista Ferres, Juan
Moraes, Milton Ozório
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Novartis Foundation. Basel, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
University of Basel. Basel, Switzerland / University Medical Center Mainz. Department of Dermatology. Mainz, Germany.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Novartis Foundation. Basel, Switzerland.
Novartis Foundation. Basel, Switzerland.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
University of Aberdeen. Aberdeen, Scotland.
Wilbraham, MA, USA.
University of Basel. Basel, Switzerland
Novartis Foundation. Basel, Switzerland.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Novartis Foundation. Basel, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
University of Basel. Basel, Switzerland / University Medical Center Mainz. Department of Dermatology. Mainz, Germany.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Novartis Foundation. Basel, Switzerland.
Novartis Foundation. Basel, Switzerland.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
University of Aberdeen. Aberdeen, Scotland.
Wilbraham, MA, USA.
University of Basel. Basel, Switzerland
Novartis Foundation. Basel, Switzerland.
Microsoft Headquarters. One Microsoft Way. Redmond, WA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Abstract
Background: Leprosy is an infectious disease that mostly affects underserved populations. Although it has been largely eliminated, still about 200’000 new patients are diagnosed annually. In the absence of a diagnostic test, clinical diagnosis is often delayed, potentially leading to irreversible neurological damage and its resulting stigma, as well as continued transmission. Accelerating diagnosis could significantly contribute to advancing global leprosy elimination. Digital and Artificial Intelligence (AI) driven technology has shown potential to augment health workers abilities in making faster and more accurate diagnosis, especially when using images such as in the fields of dermatology or ophthalmology. That made us start the quest for an AI-driven diagnosis assistant for leprosy, based on skin images. Methods: Here we describe the accuracy of an AI-enabled image-based diagnosis assistant for leprosy, called AI4Leprosy, based on a combination of skin images and clinical data, collected following a standardized process. In a Brazilian leprosy national referral center, 222 patients with leprosy or other dermatological conditions were included, and the 1229 collected skin images and 585 sets of metadata are stored in an open-source dataset for other researchers to exploit. Findings: We used this dataset to test whether a CNN-based AI algorithm could contribute to leprosy diagnosis and employed three AI models, testing images and metadata both independently and in combination. AI modeling indicated that the most important clinical signs are thermal sensitivity loss, nodules and papules, feet paresthesia, number of lesions and gender, but also scaling surface and pruritus that were negatively associated with leprosy. Using elastic-net logistic regression provided a high classification accuracy (90%) and an area under curve (AUC) of 96.46% for leprosy diagnosis. Interpretation: Future validation of these models is underway, gathering larger datasets from populations of different skin types and collecting images with smartphone cameras to mimic real world settings. We hope that the results of our research will lead to clinical solutions that help accelerate global leprosy elimination.
Keywords in Portuguese
HanseníaseInteligência artificial
AI
Diagnóstico baseado em imagem
Dermatologia
Lesões de pele
Al4lepra
Keywords
LeprosyArtificial intelligence
AI
Image-based diagnosis
Dermatology
Skin lesions
Al4leprosy
Share